RxDoctor Payments Data

Jorge Magallon, MD

Interventional Cardiology · San Antonio, TXNPI 1134154172

Payments from drug & device makers

$47,293in general payments, 2019–2025

Across 1,169 payments — averaging $40.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$10K
  • Medtronic$9K
  • Penumbra, Inc.$4K
  • Angiodynamics, Inc.$3K
  • Novartis$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • plus $17K from 52 others

What the payments were for

  • Travel & lodging$10,11921%
  • Food & beverage$37,17579%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,293 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$399,850
Medicare patients
782
Services billed
3,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan61$759,748
EntrestoSacubitril/Valsartan395$627,004
EliquisApixaban421$549,161
UptraviSelexipag18$460,288
AdempasRiociguat16$232,488
FarxigaDapagliflozin Propanediol173$223,531
JardianceEmpagliflozin126$186,921
LetairisAmbrisentan11$142,877
XareltoRivaroxaban90$131,159
Repatha SureclickEvolocumab61$75,223
BrilintaTicagrelor68$71,404
Tadalafil18$26,008
VerquvoVericiguat16$25,313
Repatha PushtronexEvolocumab12$17,978
NexlizetBempedoic Acid/Ezetimibe12$11,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$1,914$1,220,03679 claims
NovartisEntresto$2,432$627,004395 claims
PfizerEliquis$436$549,161421 claims
AstraZenecaFarxiga, Brilinta$176$294,935241 claims
BayerAdempas$35$232,48816 claims
Boehringer IngelheimJardiance$487$186,921126 claims
GileadLetairis$56$142,87711 claims
Johnson & JohnsonXarelto$1,523$131,15990 claims
MerckVerquvo$741$25,31316 claims
Esperion Therapeutics, Inc.Nexlizet$63$11,80812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →